AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly lowered the mean seated ...

Minimally invasive procedures, increasing chronic disease burden, and safety-focused innovations are driving the Peripheral IV Catheters market forward. CA, UNITED STATES, July 15, 2025 /EINPresswire.

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Your bedroom lighting choices could be silently damaging your health every night. Research shows just one night of moderate light exposure during sleep raises insulin resistance and prevents proper ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

India’s beloved snacks like samosa and jalebi may soon face health reality check. These oil soaked rich and heavy snacks may get health risk warning on pack just like label on cigarette packet.

Novartis AGNVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus Estimate for revenues is pegged at $14.04 billion, while the same for earnings ...

The benefits of intense exercise aren’t limited to the body—they also extend to the brain. Short bursts of high-effort ...